591 results about "Agglutination" patented technology

Microfluidic methods and devices for heterogeneous binding and agglutination assays are disclosed, with improvements relating to mixing and to reagent and sample manipulation in systems designed for safe handling of clinical test samples.

A device, system and method for photometric detection of coagulation in whole blood. The present invention is easy to implement and operate. Furthermore, the present invention has the advantage of being considered to fulfill the desired standard of using photometry for measuring blood coagulation. Also, a photometric coagulation test device for whole blood specimens according to the present invention provides medical accuracy to the home user and, at the same time, is simple to construct. The present invention is also useful for detecting and determining blood agglutination, for example as the results of a serological reaction with an antibody.

The invention discloses a lactobacillus plantarum and a preparation method thereof for high-density culture and freeze-drying bacteria powder, and has the technical scheme that the lactobacillus plantarum (Lactobacillus plantarum P8) is probiotics separated from the traditional fermentation milk product (yoghurt) of the Urat Middle Banner of Inner Mongolia Bayan Nur. The probiotics has the characteristics of artificial gastric juice and artificial digestive juice tolerance, cholate tolerance, intestinal agglutination action and common pathogenic entero bacteria inhibition. The bacterial strain of the bacteria is collected in the China general microbiological culture collection center with the collection number of CGMCC (China general microbiological culture collection center) No. 5468 on 18th, Nov., 2011.

An apparatus for classifying a liquid patient sample includes at least one sample container having a quantity of a sample that is aggressively acted upon so as to create a flow field. A measurement mechanism includes at least one low angle light emitter aligned with a measurement window of the at least one sample container and a detector oppositely disposed relative to the measurement window. Measurement of the scattered light detects particle characteristics of a moving flow field from the sample to determine, for example, the amount of agglutination of the sample so as to perform blood typing or other classifications without spatial separation.

The present invention relates to (1) A reagent for an immunoassay of a target substance existing in a free form and a bound form in a specimen, comprising a latex 1 which is immobilized with a monoclonal antibody 1 for the target substance, and a latex 2 which has a different mean particle size from the latex 1 and is immobilized with a monoclonal antibody 2 having a different recognition site for the target substance from the antibody 1, (2) An immunoassay method comprising reacting the target substance with the reagent of (1) and determining an amount of the substance based on the result of an agglutination reaction among the target substance, the latex1 and the latex2, and (3) A reagent kit comprising a reagent of (1) and a reagent containing an agglutination accelerator for an antigen-antibody reaction.

An object of the present invention is to provide an immunoassay of PSA using an agglutination accelerator, which has an agglutination accelerating effect equal to or stronger than the known agglutination accelerator; hardly generates non-specific turbidity; and hardly generates salting out even in a solution with a high salt concentration. The present invention relates to an immunoassay of a prostate-specific antigen comprising performing an antigen-antibody reaction in the presence of a polymer having a monomer unit derived from a monomer represented by the following general formula [2]: (wherein R<1>-R<3 >are each independently a hydrogen atom or an alkyl group optionally having a hydroxyl group; R<4 >is an alkylene group; R<5 >is an alkylene group optionally having a substituent and optionally having an oxygen atom in a chain; R<6 >is a hydrogen atom or a methyl group, and X is an oxygen atom or a -NH- group), and a kit of reagent for an immunoassay comprising a reagent containing an agglutination accelerator for the immunoassay.

Disclosed is an oil soluble pesticide nm capsule and preparation method, having weight ration of: pesticide: 0.5-4%; high molecular compound: 8-25%; mixed-surfactant: 8-20%; cosurfactant 3-10%; crosslinking agent 0.5-1.0%; organic solvent 3-10%; water: added to 100%, wherein the high molecular compound is selected from sodium lignosulfonates, chitosan, gum arabic or glutin, one or two is/are selected for agglutination reaction, forming capsule skin of the nm capsule; the capsule core is pesticide bulk drug, selected from diflubenzuron, emamectin benzoate, abamectin, imidacloprid, ivermectin or highly active cypermethrin. The mixed-surfactant adopts nonionic surfactant and anionic surfactant for compound. The pesticide nm controlled release preparation prepared by the invention is easy in storage, high in stability, large in drug-loading rate and high in dispersion.

The present invention describes a tunable micro-antenna of reduced electrical dimensions. This antenna consists of the agglutination of several substrate layers (11), identical or distinct, with electrical, thermal and mechanical properties compatible with the manufacturing processes of integrated circuits. These layers are interleaved with metallic sheets (12) that are interconnected by metallized walls or vias, in such a way that they form a radiating structure (15) and a ground plane (14). The radiating structure includes slots in one or more levels, therefore allowing a greater reduction of the antennas' electrical length. These slots may include switches, used to render the antenna tunable. Since the entire manufacturing method is compatible with the wafer level packaging technology, the micro-antenna is easily integrable in microsystems requiring wireless communication

The invention discloses a preparation method for SnO2/SnS2 heterostructure photocatalyst. The preparation method includes following steps: (1) preparing SnO2 nanometer particles by an alcohothermal method; and (2) and performing in-situ synthesis for SnO2/SnS2 into heterostructure in an ion exchange method. The preparation method has the advantages that a preparation process is simple and convenient, controllability of reaction conditions is high, more importantly, SnO2 and SnS2 can be uniformly compounded, and accordingly more stable contact is provided to conduct charge and prevent auto-agglutination. When illuminated by visual light (>420nm), the SnO2/SnS2 heterostructure photocatalyst has good photocatalysis activity, the photocatalysis activity is the best after the SnO2/SnS2 heterostructure photocatalyst is heated by a kettle for 30 hours, the degradation degree of the SnO2/SnS2 heterostructure photocatalyst can basically reach 100% after the SnO2/SnS2 heterostructure photocatalyst is heated by the kettle for 4 hours, and the preparation method has a potential application value in the aspect of comprehensive ecological improvement, particularly dye wastewater pollution treatment.

The invention relates to the technical field of medical examination, and particularly relates to a latex immunoturbidimetry serum pepsinogen I detection kit for eliminating chyle interference. The kit provided by the invention comprises (1) a pepsinogen I calibrator; (2) a reagent 1 with a preset chyle remover; and (3) a reagent 2 containing the monoclonal antibody and polyclonal antibody coated latex particles against human pepsinogen I. According to the kit provided by the invention, the combination reaction between a substrate to be detected in a sample and a specific antibody in the reagent is amplified through the latex agglutination effect; with the given wavelength, the turbidity formed by the reaction is related to the content of the substrate to be detected, thus the content of the substrate to be detected is calculated. The kit provided by the invention is used for detecting the content of pepsinogen I in human serum, has high sensitivity and good specificity, and can eliminate chyle interference in the sample; moreover, the kit is simple and quick to operate and has high practicability and wide application range.

A method and system are described for measuring agglutination in a target-induced agglutination assay with one or more magnetic particles performed in a reaction chamber. After the magnetic particles (3, 15), which are capable of binding to a target (5) are provided in the assay, an agglutination process resulting in agglutinated particles (100) comprising at least one magnetic particle is performed. The method then further comprises applying an alternating current magnetic field (H_AC) to the assay and—measuring an effect of the H_AC on the one or more magnetic particles (3,15) unattached to any surface. The measured effect is indicative of one or more agglutination parameters.

A method is providing for measuring platelet reactivity of a PCI patient that has a (DES). A blood sample is obtained from the patient. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the mixture. The absence of agglutination indicates that the patient has reduced ability to form platelet thrombi.

The invention provides an immunological analytical method and devices for determination of the advanced glycosylation end products (AGEs), comprising a reagents for determining the AGEs, which comprises a displaying carrier suspension and the antigen or antibody immobilized on the surface of the said displaying carrier; and a test strip, comprising of: a base plate, and constitutive parts provided on the said base plate. After infusing the said reagent into the said test strip, the immunological reaction of the AGEs antigen or antibody can be determined based on the agglutination phenomenon or accompanied changes of absorbance or color and the presence or raised level of the AGEs in the diabetic patient can be known accordingly such that the practitioner can prevent the occurrence of the complications, or block further the progression of the complications at the earlier stage.